Based on the earnings call transcript, Merck & Co. Inc. reported strong third-quarter results, driven by robust sales of new vaccines like GARDASIL and ROTATEQ, as well as sustained growth from established franchises like SINGULAIR and JANUVIA. The company also provided optimistic guidance for the full year 2007, raising its EPS range to $3.08 to $3.14, excluding restructuring charges. Additionally, the company announced plans to launch ISENTRESS in the fourth quarter and continued to expand its product portfolio through strategic acquisitions and partnerships. Overall, the company's performance and guidance suggest a positive outlook for the remainder of 2007 and beyond.